

Learner Notification

MED Learning Group

Advancements in Precision Medicine: TROP-2 Antigen as a Tumorigenic Driver in Breast Cancer

February 2, 2024 – February 2, 2025

Online

Acknowledgement of Financial Commercial Support

AstraZeneca, Daiichi Sankyo, Inc.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Discuss the role of trophoblast cell-surface antigen 2 (TROP-2) in the proliferation, invasion, migration, and survival of cancer cells.
2. Review the clinical trial findings documenting the efficacy of TROP-2-targeted compounds in patients with advanced breast cancer.
3. Examine the adverse effects most commonly associated with antibody-drug conjugates (ADCs) and the methods of managing them in patients with advanced breast cancer.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Russie	Allen	NA
Millena	Debritto	NA
Kim	Farina	NA
Matthew	Frese	NA
Christina	Gallo	NA
Amanda	Jenkins	NA
Melissa	Johnson	NA
Kevin	Kalinsky	Genentech/Roche, Immunomedics, Seattle Genetics, OncoSec, 4D Pharma, Daiichi Sankyo, Puma Biotechnology, Mersana Therapeutics, Menarini Silicon Biosystems, Myovant Sciences, Takeda: Consultant; EQRx, Grail, Array BioPharma, Pfizer: Ownership Interests
Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email Certificate@AmedcoEmail.com